巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02367 巨子生物

收市竞价 09-28 16:04:15

24.280

+0.240

+1.00%

最高24.860	最低24.080	成交量160.32万
今开24.080	昨收24.040	日振幅3.24%
总市值257.85亿	流通市值257.85亿	总股本10.62亿
成交额3,897万	换手率0.15%	流通股本10.62亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02367","market":"HK","secType":"STK","nameCN":"巨子生物","latestPrice":24.28,"timestamp":1790582461837,"preClose":24.04,"halted":0,"volume":1603184,"delay":0,"changeRate":0.00998336106489193,"floatShares":1061999999,"shares":1061999999,"eps":1.809999,"marketStatus":"收市竞价","change":0.24,"latestTime":"09-28 16:04:15","open":24.08,"high":24.86,"low":24.08,"amount":38970022,"amplitude":0.032446,"askPrice":24.28,"askSize":35800,"bidPrice":24.28,"bidSize":29400,"shortable":3,"etf":0,"ttmEps":1.81589,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1790583000000},"marketStatusCode":4,"adr":0,"listingDate":1667491200000,"exchange":"SEHK","adjPreClose":24.04,"dividendRate":0.057228,"openAndCloseTimeList":[[1790559000000,1790568000000],[1790571600000,1790582400000]],"volumeRatio":0.742542,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02367","defaultTab":"news","newsList":[{"id":"1130879572","title":"巨子生物2026年中期营收29.2亿元，经调整净利润9.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1130879572","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130879572?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:37","pubTimestamp":1790242661,"startTime":"0","endTime":"0","summary":"根据巨子生物公告，2026年上半年实现营收29.2亿元，同比下降6.3%。同期经调整净利润约为9.5亿元，同比下降21.5%。毛利率由上年同期的81.7%下降至79.5%。公司报告期内销售及经销开支约为12.67亿元，同比上涨19.7%；行政开支约为79.9百万元，同比下降3.3%；研发支出约为0.46亿元，占营收比约1.6%。经营活动所产生的现金净额约为7.90亿元，高于上年同期的7.16亿元。公告指出，可复美营收下滑主要因市场竞争加剧及渠道结构调整。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"巨子生物2026年中期营收29.2亿元，经调整净利润9.5亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669115400","title":"【券商聚焦】华创证券维持巨子生物（02367）推荐评级 指医美新品打开增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2669115400","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669115400?lang=zh_cn&edition=full","pubTime":"2026-09-22 13:40","pubTimestamp":1790055658,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华创证券发布研报指，巨子生物 2026年上半年业绩阶段性承压，但医美新品打开增长新空间。业务拆分方面，核心品牌可复美收入23.47亿元，同比-7.7%，占总收入80.4%，下滑主要受行业竞争及达播端收入结构性调整影响，下半年低基数预计增速环比改善；可丽金收入4.99亿元，同比-0.8%，基本保持稳定。618大促期间可复美与可丽金线上全渠道GMV分别同比增长超25%和30%。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992194","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","02367","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668130949","title":"【券商聚焦】华泰证券：韩妆增长逻辑拆解与国潮美妆出海展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2668130949","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668130949?lang=zh_cn&edition=full","pubTime":"2026-09-18 08:40","pubTimestamp":1789692020,"startTime":"0","endTime":"0","summary":"华泰证券认为K-Beauty以韩流带动的审美潮流、高效快反的ODM供应链、高转化的内容电商等为抓手,成功走向欧美。华泰证券认为，国货同样具备供应链/营销/体验等优势，国潮文化或成东方美出海的重要催化剂。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991906","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","LU0164865239.USD","LU1328615791.USD","LU1580142542.USD","LU0871576103.HKD","LU2242644610.SGD","BK0188","LU2148510915.USD","BK0183","LU0039217434.USD","LU1934453819.USD","601688","LU0348767384.USD","01318","LU1979443071.USD","LU0502904849.HKD","SG9999004311.SGD","LU1064130708.USD","KCE","02367","BK0276","BK1207","BK0028","02145","BK0012","LU0531971595.HKD","LU1808992512.USD","LU1064131003.USD","LU0455707207.USD","LU2488822045.USD","02657","LU1781817850.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695232","title":"长坡厚雪 “巨子”焕新","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695232","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667695232?lang=zh_cn&edition=full","pubTime":"2026-09-15 04:27","pubTimestamp":1789417674,"startTime":"0","endTime":"0","summary":"2026年初秋，西安。巨子生物基础研发中心内，精密仪器的指示灯微微闪烁，科研人员紧盯着屏幕上跳动的实验数据。在实验室之外，市场团队正在为可丽金“芯生”753胶原针的全国机构铺货忙碌。这款新上市的产品，短短两个月便已进入约300家医美机构——这也意味着，巨子生物这家重组胶原蛋白领域的龙头企业，正式踏入了专业医美注射这条新赛道。对巨子生物而言，2026年注定是希望与压力交织的一年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153873814080.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153873814080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","02367","SG9999004311.SGD","BK1207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666630557","title":"【券商聚焦】招银国际：重点港股消费股的仓位结构趋于稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2666630557","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666630557?lang=zh_cn&edition=full","pubTime":"2026-09-10 13:21","pubTimestamp":1789017678,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际表示，截至9月8日的两周，重点港股消费股的仓位结构趋于稳定。平均未平仓沽空占自由流通股比例微升0.1ppt至8.8%，仍处于近半年高位附近；随着中报季成交回归常态，空头回补天数由8.5天回落至8.3天。南下持股占自由流通股比例上升0.8ppt至31.7%，为1Q26以来首次显著回升，尽管8月南向资金整体净流入约104亿港元，较7月的约629亿港元明显放缓。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991290","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0871576103.HKD","KCE","LU0164865239.USD","BK1207","02367","LU0823426480.USD","LU1880383440.USD","09896","LU0572944931.SGD","BK1544","SGXZ90724238.SGD","LU0593848301.USD","06181","02097","LU0149721374.USD","LU0307460666.USD","SGXZ86797644.SGD","02555","02589","SG9999002950.SGD","LU2488822045.USD","LU0039217434.USD","BK1616","00325","LU0359201885.HKD","LU0611395673.USD","LU0359201612.USD","LU1880383366.USD","LU0231483743.USD","LU0359202008.SGD","SG9999001051.SGD","LU2543165471.USD","LU0823426308.USD","BK1246","IE0034224299.USD","01364","09992","LU0211977185.USD","LU0499858438.USD","BK1587","159735","02150","LU0345776255.USD","LU1770036033.HKD","01318","BK1233","LU0164880469.USD","LU0531971595.HKD","LU1023057109.AUD","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666545565","title":"美妆板块走弱 上美股份（02145）跌3.51% 机构指行业利润端整体分化加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2666545565","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666545565?lang=zh_cn&edition=full","pubTime":"2026-09-10 10:57","pubTimestamp":1789009076,"startTime":"0","endTime":"0","summary":"金吾财讯 | 美妆板块盘中走弱，截至发稿，上美股份（02145）跌3.51%，巨子生物（02367）跌1.15%，毛戈平（01318）跌0.21%。消息面上，申万宏源新近研究指，化妆品行业26H1营收端具备韧性，利润端持续分化。受需求端回暖影响，化妆品品牌端26Q2营收端整体来说环比边际改善明显，头部国货公司依托多品牌矩阵、产品迭代实现稳健增收增利，经营质量持续优化。但受投流费用持续上涨、国际品牌加剧竞争等因素影响，利润端整体分化加剧。部分品牌呈现增收不增利的趋势。化妆品制造端保持稳定运营，代工企业依托大客户订单与产能释放实现营收增长，但原材料及加工竞争压缩溢价空间，整体毛利率略有承压。","market":"other","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991237","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1224","LU0502904849.HKD","BK1525","LU0348766576.USD","SG9999004311.SGD","BK1502","LU2488822045.USD","02145","00178","BK1601","BK1602","LU0348767384.USD","LU0455707207.USD","BK1207","01318","LU2242644610.SGD","BK1577","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398249","title":"【券商聚焦】中信建投：上半年收入与利润双增，医药行业步入新发展周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398249","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398249?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:04","pubTimestamp":1788743053,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业整体收入与扣非净利润实现双增长，创新药、CXO、制药装备及科学试剂等板块积极复苏，行业步入新发展周期。创新药收入+58.68%，扭亏为盈，出海总金额超900亿美元，全年有望超越2025年水平，国际化持续兑现；CXO收入+25.2%，扣非净利润+66.5%，订单旺盛，上行周期确立。随着集采出清、创新放量、出海落地及上游国产化提升，行业有望开启高质量发展周期，龙头将持续受益。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990791","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","02196","LU0417516902.SGD","02367","BK1141","LU2778985437.USD","BK1207","BK1515","SG9999004311.SGD","IE00B3M56506.USD","01099","BK1593","IE00BPRC5H50.USD","09688","BK1583","02228","BK1197","IE00B5MMRT66.SGD","01789","01530","06821","BK1161","LU2488822045.USD","LU2476274720.SGD","LU0348827113.USD","LU0228659784.USD","06160","BK1574","02268","KURE","LU2328871848.SGD","BK1191","03933","KCE","LU2399975544.HKD","BK1585","LU1115378108.SGD","09926","BK1500","LU1770034418.SGD","601066","LU0640798160.USD","BK1588","LU0348825331.USD","LU0588546209.SGD","LU2476274308.USD","LU1969619763.USD","LU0828237510.HKD","BK1100","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664382615","title":"【券商聚焦】华源证券维持巨子生物（02367）买入评级 期待H2盈利拐点向上","url":"https://stock-news.laohu8.com/highlight/detail?id=2664382615","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664382615?lang=zh_cn&edition=full","pubTime":"2026-09-04 15:18","pubTimestamp":1788506304,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华源证券发布研报指，巨子生物 26H1实现收入29.2亿元，同比-6.3%；净利润9.4亿元，同比-20.5%；经调净利润9.5亿元，同比-21.5%。短期业绩承压，但伴随新品上市落地，下半年销售费用投入及净利率表现有望持续恢复，期待H2盈利拐点向上，维持“买入”评级。可丽金实现收入4.99亿元，同比几乎持平。华源证券预计2026-28年公司归母净利润为19.8/22.2/24.8亿元，同比增长+3.4%/12.2%/11.8%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990730","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","KCE","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167453302","title":"巨子生物8月无新增发行或股份变动，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1167453302","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167453302?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:46","pubTimestamp":1788425195,"startTime":"0","endTime":"0","summary":"巨子生物控股有限公司于2026年9月3日披露了截至2026年8月31日的月度证券变动报告。报告显示，公司在本月内法定及注册股本、已发行股份及库存股份数量均保持不变。已发行股份总数依旧为1,061,704,000股，未出现任何新增发行、购回、注销或库藏股变动。公司在公告中确认，所有股份变动及披露均遵守香港联交所《上市规则》和相关法律法规要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887532","title":"美妆股走强 毛戈平（01318）涨4% 机构指板块基本面稳步修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887532","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664887532?lang=zh_cn&edition=full","pubTime":"2026-09-01 10:39","pubTimestamp":1788230355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 美妆股走强，毛戈平（01318）涨4.00%，上美股份（02145）涨3.32%，巨子生物（02367）涨1.86%。华龙证券近日研报指，政策层面，美妆行业监管优化与产业创新共振，化妆品新原料目录扩容持续降低企业研发备案门槛，同时推动AI技术、生物科技与护肤研发深度融合，行业高质量创新发展态势明确。当前板块基本面稳步修复，品牌出海、科技护肤等细分赛道机遇凸显。维持美容护理行业“推荐”评级。万联证券提到，消费分级时代，潮玩、古法金、国货美妆等情绪消费赛道景气度高企。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990193","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","SG9999004311.SGD","LU0348766576.USD","02145","LU0348767384.USD","LU2242644610.SGD","BK1207","LU0502904849.HKD","02367","01318","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662780170","title":"巨子生物上半年营收净利双降：可复美业绩失速，可丽金未逆袭","url":"https://stock-news.laohu8.com/highlight/detail?id=2662780170","media":"南方都市报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662780170?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:18","pubTimestamp":1787649522,"startTime":"0","endTime":"0","summary":"近日，巨子生物发布2026年中期业绩公告，这份成绩单打破了市场此前对其重回增长的期待。公告显示，公司营业收入29.18亿元，同比下滑6.3%；归属于本公司权益股东的利润约为9.4亿元，同比下跌20.5%，经调整净利润约9.5亿元，同比下降21.5%，利润端的降幅显著高于营收端，这家顶着“重组胶原蛋白第一股”光环的昔日高增长明星企业，正在经历上市之后的业绩承压期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608253852927356.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608253852927356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661956225","title":"【券商聚焦】东北证券维持巨子生物（02367）买入评级 指公司研发壁垒深厚","url":"https://stock-news.laohu8.com/highlight/detail?id=2661956225","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661956225?lang=zh_cn&edition=full","pubTime":"2026-08-24 14:13","pubTimestamp":1787552035,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东北证券发布研报指，巨子生物 发布2026年中期业绩，2026H1实现营收29.18亿元，同比下降6.26%；净利润9.40亿元，同比下降20.50%；经调整净利润9.5亿元，同比下降21.5%。研报指出，分品牌看，可复美营收23.47亿元，占比80.4%，同比下降7.7%；可丽金营收4.99亿元，占比17.1%，同比仅微降0.8%，展现韧性。618大促中，可复美线上全渠道全周期GMV同比增长超过25%，可丽金同比增长超过30%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989129","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000686","KCE","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661470562","title":"砍掉达人直播后，巨子生物每卖100元货仍要花43元推销","url":"https://stock-news.laohu8.com/highlight/detail?id=2661470562","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661470562?lang=zh_cn&edition=full","pubTime":"2026-08-24 11:19","pubTimestamp":1787541561,"startTime":"0","endTime":"0","summary":"可复美一个品牌的收入下滑，就几乎吞噬了巨子生物全部的营收增量——这正是半年报里最刺眼的数据。上半年，这个占比超八成的超级单品收入从25.42亿元跌至23.47亿元，而公司整体营收不过从31.13亿元降至29.18亿元。为了摆脱对头部主播的依赖，巨子生物主动收缩达人直播渠道，代价是销售费用率飙升到43.4%，每挣100元就要花掉43元推销。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608243850893374.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608243850893374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1207","SG9999004311.SGD","02367","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661257368","title":"港股异动 | 巨子生物(02367)再跌超6% 公司主动调整渠道结构 上半年业绩有所承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2661257368","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661257368?lang=zh_cn&edition=full","pubTime":"2026-08-21 14:21","pubTimestamp":1787293278,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，巨子生物(02367)再跌超6%，截至发稿，跌5.95%，报27.84港元，成交额1.18亿港元。消息面上，巨子生物发布业绩，上半年收入约29.18亿元，同比减少6.3%；归母净利润9.4亿元，同比减少20.5%。业绩承压主要系公司主动调整渠道结构，达人直播占比下降，以及加大品牌以及新品宣传，但公司仍聚焦长期经营质量、夯实渠道与产品竞争力。广发证券指出，低基数+新品放量，看好26H2增长修复。公司品牌势能企稳回升，两大主品牌618大促表现亮眼。未来护肤端看好超透棒等新品放量及渠道结构优化调整，医美端伴随胶原三类械商业化落地，有望打开第二增长曲线，驱动公司业绩重回增长轨道。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","SG9999004311.SGD","KCAI","BK1207","02367","LU2488822045.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102026058","title":"异动解读｜巨子生物盘中下跌5.14%，招商证券将评级下调至卖出并给出25港元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1102026058","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102026058?lang=zh_cn&edition=full","pubTime":"2026-08-21 11:04","pubTimestamp":1787281444,"startTime":"0","endTime":"0","summary":"8月21日，巨子生物盘中下跌5.14%，报28.08港元，成交额5620.08万港元。消息面上，招商证券将巨子生物评级从持有下调至卖出，目标价25港元，显著低于当前股价，与此前花旗、东吴证券、国金证券等机构集体维持买入评级形成明显分歧，打压市场情绪。公司8月18日披露的中期业绩显示收入29.18亿元同比下降6.3%，归母净利润9.40亿元同比下降20.5%，核心品牌可复美表现承压，销售费用同比增长近两成。前一交易日股价反弹近5%后，利空评级再度引发抛压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"巨子生物盘中下挫，招商证券罕见下调至卖出","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142041555","title":"异动解读｜巨子生物盘中上涨5.7%，多家券商绩后集体维持买入评级提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1142041555","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142041555?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:50","pubTimestamp":1787190645,"startTime":"0","endTime":"0","summary":"8月20日，巨子生物盘中上涨5.7%，报29.94港元，成交额9724.02万港元。消息面上，公司8月18日盘后发布中期业绩，收入29.18亿元同比下降6.3%，归母净利润9.40亿元同比下降20.5%，业绩公布次日股价一度跌近6%。然而随后多家机构集体力挺：花旗将目标价上调至38.4港元并列为中国化妆品板块首选买入股，东吴证券、国金证券均维持买入评级，认为至暗时刻已过。管理层维持全年收入增长10%及净利润持平的指引，市场情绪在超跌后出现修复。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"巨子生物盘中上涨5.7%，多家券商绩后集体维持买入评级提振情绪","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660442084","title":"可复美失守、业绩连降，巨子生物高增长神话褪色","url":"https://stock-news.laohu8.com/highlight/detail?id=2660442084","media":"北京商报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660442084?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:49","pubTimestamp":1787136580,"startTime":"0","endTime":"0","summary":"从高增长到营利双降，巨子生物的业绩颓势仍未扭转。8月18日晚间，巨子生物发布2026年中期报告，上半年收入29.18亿元，同比下降6.3%；归属于公司权益股东的利润则同比下降20.5%。2025年，巨子生物出现上市以来首次营收、净利润双降，今年上半年颓势不仅未止，净利润降幅反而进一步扩大。核心品牌“可复美”是主要业绩拖累因素。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608193846429783.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608193846429783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","BK1207","02367","SG9999004311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660410584","title":"销售费用大增近2成，巨子生物的流量账单越来越贵","url":"https://stock-news.laohu8.com/highlight/detail?id=2660410584","media":"华尔街见闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660410584?lang=zh_cn&edition=full","pubTime":"2026-08-19 14:46","pubTimestamp":1787121971,"startTime":"0","endTime":"0","summary":"8月18日晚，巨子生物发布2026年中期业绩。上半年实现收入29.18亿元，同比下降6.3%；同期净...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3779780","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1207","02367","SG9999004311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660041711","title":"【券商聚焦】东吴证券维持巨子生物（02367）买入评级 指至暗时刻已过","url":"https://stock-news.laohu8.com/highlight/detail?id=2660041711","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660041711?lang=zh_cn&edition=full","pubTime":"2026-08-19 14:29","pubTimestamp":1787120961,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东吴证券发布研报指，巨子生物 公布2026年上半年业绩，实现营收29.2亿元，同比下滑6.3%；归母净利润9.4亿元，同比下滑20.5%；经调整净利润9.5亿元，同比下滑21.5%。研报认为，短期业绩有所承压，但618大促展现品牌韧性，产品矩阵与医美新品逐步进入兑现期，至暗时刻已过。东吴证券维持2026-2028年归母净利润预测19.78/22.70/26.58亿元，同比分别增长3%/15%/17%，最新收盘价对应2026-2028年PE为13/11/10倍，维持“买入”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988712","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601555","KCE","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660417197","title":"【券商聚焦】国金证券维持巨子生物（02367）买入评级 指医美新品开启第二曲线","url":"https://stock-news.laohu8.com/highlight/detail?id=2660417197","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660417197?lang=zh_cn&edition=full","pubTime":"2026-08-19 14:29","pubTimestamp":1787120954,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券发布研报指，巨子生物 2026年上半年实现营收29.2亿元，同比-6.3%，归母净利润9.4亿元，同比-20.5%。医美业务正式商业化，首款产品753胶原针上市，成功开启第二增长曲线。随着下半年渠道调整逐步到位、护肤品业务在低基数下恢复增长，以及医美新品的持续放量，公司有望重回增长轨道。国金证券预测公司2026/2027/2028年归母净利润为19.81/22.38/25.16亿元，EPS为1.87/2.11/2.37元，对应PE为14/12/11倍，维持“买入”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988713","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367","KCE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xajuzi.com","stockEarnings":[{"period":"1week","weight":-0.0091},{"period":"1month","weight":-0.1162},{"period":"3month","weight":-0.0682},{"period":"6month","weight":-0.1315},{"period":"1year","weight":-0.5306},{"period":"ytd","weight":-0.2426}],"compareEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":-0.0446},{"period":"3month","weight":0.0811},{"period":"6month","weight":-0.0177},{"period":"1year","weight":-0.0746},{"period":"ytd","weight":-0.0437}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"巨子生物控股有限公司是一家主要从事基于生物活性成分的美丽与健康产品的研发、制造及销售业务的投资控股公司。该公司的主要产品包括功效性护肤品、医用敷料等专业皮肤护理产品，以及保健食品及其他产品。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.063748},{"month":2,"riseRate":0.75,"avgChangeRate":0.082293},{"month":3,"riseRate":0.75,"avgChangeRate":0.04973},{"month":4,"riseRate":0.75,"avgChangeRate":0.023756},{"month":5,"riseRate":0.25,"avgChangeRate":-0.038833},{"month":6,"riseRate":0.25,"avgChangeRate":-0.059254},{"month":7,"riseRate":0.5,"avgChangeRate":0.005281},{"month":8,"riseRate":0.5,"avgChangeRate":-0.026722},{"month":9,"riseRate":0.5,"avgChangeRate":0.029638},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.12614},{"month":11,"riseRate":0.333333,"avgChangeRate":0.019826},{"month":12,"riseRate":0.25,"avgChangeRate":0.047111}],"exchange":"SEHK","name":"巨子生物","nameEN":"GIANT BIOGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"巨子生物,02367,巨子生物股票,巨子生物股票老虎,巨子生物股票老虎国际,巨子生物行情,巨子生物股票行情,巨子生物股价,巨子生物股市,巨子生物股票价格,巨子生物股票交易,巨子生物股票购买,巨子生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}